What Lacristat does

LacriStat.AI is a private ophthalmic technology company headquartered at an ophthalmic incubator in Menlo Park, California, developing AI-enabled tear biomarker sensing platforms. The company originated from teams at Verily (Google Life Sciences), Google, and Twenty/Twenty Therapeutics, where founders previously worked on smart contact lens and ophthalmic innovation projects. The company operates with a headcount of 1–10 employees and is led by CEO Dimitri Azar MD, MBA, a former tenured Harvard professor and University of Illinois College of Medicine executive dean.

The company's technology stack combines AI-driven analytics, proprietary nano-fluidics, microelectronics, and (in development) cell therapy. It commercializes this stack through two core products: LacriStat™, an AI-powered continuous tear biomarker monitoring platform for dry eye disease management using real-time diagnostic insights and personalized treatment plans; and LacriSync™, a non-invasive tear-based nanosensor that captures LH surge (~44.6 IU/L) and FSH peaks to optimize IUI and IVF treatment timing, replacing 15+ invasive blood draws per fertility cycle with 1-year-stable continuous monitoring. The company is also developing disease-modifying cell therapies for ocular tissue regeneration.

The business model is enterprise hardware sales combined with an enterprise field sales motion targeting ophthalmology clinics, eye care providers, fertility treatment centers, and REI specialists. Pricing is not publicly disclosed, and there is no evidence of commercial revenue or completed funding rounds in the source material. Commercialization is being supported through an academic partnership stack spanning Stanford Byers Eye Institute, Harvard/Mass Eye and Ear, Johns Hopkins Wilmer Eye Institute, UIC, UCSD, Bascom Palmer, and UT Dallas, with TFOS board participation extending reach into 80+ countries of tear film and ocular surface research. Marketing is conducted through LinkedIn with planned X and blog channels.

Name

Lacristat

Legal name

LacriStat.AI

Website

https://lacristat.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

LacriStat.AI is a private ophthalmic technology company developing AI-powered tear biomarker sensing platforms — LacriStat™ for dry eye disease and LacriSync™ for non-invasive fertility hormone monitoring — targeting ophthalmology clinics and fertility treatment centers.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

akta.pro secondary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Ophthalmic diagnostics
• Tear biomarker sensing
• Dry eye treatment
• Fertility monitoring devices
• Medical device innovation

Headquarters

HQ city

San Jose

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. LacriStat™ Dry Eye Diagnostic Platform: AI-powered continuous monitoring system for tear biomarkers enabling personalized dry eye disease management through real-time diagnostic insights
2. LacriSync™ Fertility Monitoring System: Non-invasive tear-based hormone sensing platform for tracking LH and FSH fluctuations to optimize IUI and IVF treatment timing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Lacristat.AI develops and sells proprietary tear biomarker remote sensing medical device platforms. LacriStat™ uses AI, nano-fluidics, and microelectronics to continuously monitor dry eye disease biomarkers for personalized treatment. LacriSync™ uses a tear nanosensor to non-invasively measure LH, FSH, and estradiol levels to optimize IUI and IVF fertility treatment timing. Both products are sold to healthcare institutions including ophthalmology clinics, fertility centers, and academic medical centers.

Product overview

LacriStat.AI offers two distinct core products: LacriStat™ for dry eye disease management and LacriSync™ for women's health/infertility diagnostics. Both products share a common technology platform centered on tear biomarker sensing using proprietary nano-fluidics and microelectronics integration. LacriStat™ focuses on continuous monitoring of tear film biomarkers to enable personalized dry eye treatment, while LacriSync™ applies the same tear-sensing technology to track hormonal fluctuations (LH, FSH, estradiol) for fertility treatment optimization. The platform is unified by AI-driven analytics and closed-loop feedback capabilities, aiming to provide real-time, personalized insights for both ophthalmic and reproductive health applications.

Differentiator

Problem solved

Functional benefit

Brands

• LacriStat™: Tear biomarker remote sensing solution for dry eye care, utilizing AI, nano-fluidics, and microelectronics for continuous monitoring.
• LacriSync™

Products and services

• LacriStat™ A groundbreaking tear biomarker remote sensing platform for continuous monitoring of dry eye disease. Uses AI-driven diagnostics, nano-fluidics technology, and microelectronics integration to provide real-time insights into eye health, enabling personalized treatment plans for ophthalmology clinics and eye care providers.
• LacriSync™ A remote, non-invasive infertility diagnostic platform that replaces traditional blood draws with tear nanosensing technology to measure LH, FSH, and estradiol levels with clinical accuracy. Designed to optimize the timing of IUI and IVF treatments by tracking hormonal fluctuations in real-time for fertility treatment centers and REI specialists.

Quantifiable outcome

• Captures LH surge (~44.6 IU/L) and FSH peaks with clinical accuracy via non-invasive tear sensing
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• Stanford University (Byers Eye Institute)coreStrategic or Co-development PartnerCollaboration with Stanford's Byers Eye Institute for clinical research and development. Dr. Jeff Goldberg serves as Professor and Chair of Ophthalmology and Director of the Byers Eye Institute. Dr. David Myung serves as Associate Professor and Director of the Ophthalmic Innovation Program at Stanford.
• Harvard UniversitycoreStrategic or Co-development PartnerPartnership with Harvard Medical School affiliated institutions including Mass Eye and Ear, Schepens Eye Research Institute. Dr. David Sullivan served as Associate Professor at Harvard Medical School and Senior Scientist at SERI. Dr. Carlos Belmonte was visiting professor at Harvard.
• Johns Hopkins University (Wilmer Eye Institute)coreStrategic or Co-development PartnerCollaboration with Johns Hopkins Wilmer Eye Institute for dry eye research. Advisor Dr. Everardo Hernandez-Quintela serves at Wilmer Eye Institute locations in Baltimore and Lutherville, Maryland.
• University of California San Diego (UCSD)secondaryStrategic or Co-development PartnerAcademic research partnership for advancing dry eye disease research and diagnostics development.
• University of Illinois Chicago (UIC)coreStrategic or Co-development PartnerPartnership with University of Illinois College of Medicine. CEO Dr. Dimitri Azar served as executive dean and distinguished professor at UIC. Dr. Ali Djalilian serves as Professor at Illinois Eye and Ear Infirmary, UIC.
• University of Miami (Miller School of Medicine - Bascom Palmer Eye Institute)secondaryStrategic or Co-development PartnerAcademic collaboration with Bascom Palmer Eye Institute. Advisor Dr. Victor Perez serves as Professor and Higgins Clark Chair in Ophthalmology at University of Miami Miller School of Medicine.
• University of Texas at DallassecondaryStrategic or Co-development PartnerAcademic research partnership contributing to dry eye disease research ecosystem.
• Tear Film & Ocular Surface Society (TFOS)coreStrategic or Co-development PartnerTFOS is a non-profit organization advancing research, literacy, and education in tear film and ocular surface science. CEO Dr. Dimitri Azar serves on TFOS board. Dr. David Sullivan is founder, recent President, and Chairman of the Board of TFOS.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• OCULUS Optikgeräte: Specializes in ophthalmic diagnostic instruments including dry eye assessment devices (Keratograph), directly competing with the LacriStat tear biomarker platform in clinical eye care settings.
• Mira: Direct-to-consumer and clinical fertility hormone monitoring company using urine-based quantitative LH, FSH, and PdG tracking; competes head-to-head with LacriSync on non-invasive hormone monitoring for fertility treatment timing.
• TearScience (Johnson & Johnson Vision): TearScience, acquired by J&J Vision, commercializes LipiFlow and LipiScan for dry eye diagnosis and treatment — the dominant installed-base competitor in ophthalmic dry eye diagnostics that LacriStat must displace.
• Sensimed: Developed the Triggerfish contact lens sensor for 24-hour intraocular pressure monitoring in glaucoma; the closest analog to LacriStat as a wearable ophthalmic biosensor with continuous data capture.

Broad incumbents

• Alcon: Global ophthalmic medical device incumbent with extensive surgical, vision care, and dry eye portfolios; represents the broad competitive landscape in ophthalmic devices and diagnostics where LacriStat would seek adoption.
• Bausch + Lomb: Diversified ophthalmic medical device and consumer vision care company with established dry eye, cataract, and pharmaceutical offerings; a broad incumbent with overlapping diagnostic and treatment capabilities.
• Abbott Diagnostics: Global in vitro diagnostics leader with fertility, hormone, and women's health testing portfolios; represents the incumbent clinical laboratory and POC diagnostic alternative that LacriSync tear-based sensing must displace.

Others

• Verily (Alphabet): Alphabet's life sciences subsidiary and Lacristat's organizational parent lineage; Verily has publicly pursued smart contact lens biosensing programs for glucose and other analytes, making it both a potential partner/competitor and IP-overlap concern.

Emerging players

• Modern Fertility (Ro): Consumer-focused fertility hormone testing service (now part of Ro) targeting women considering or undergoing fertility treatment; an emerging competitor in the same patient demographic that LacriSync aims to serve.
• Proov: At-home PdG and ovulation testing brand serving the fertility/IUI/IVF patient journey; an emerging competitor in non-invasive fertility hormone monitoring that addresses overlapping customer pain points.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xtwitter.com/lacristat
• LinkedInlinkedin.com/company/lacristat

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lacristat